Protagonist seeks an Ideal readout
A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.
The bubble bursts for biotech stocks
After a frothy couple of years, biotechs are no longer seeing big boosts from clinical data.
Early Morphic data hint at a threat to Entyvio
Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.
Back to business for biotech flotations
After a quiet first quarter demand for new issues has returned to levels seen in 2018, itself a record year for IPOs of young drug developers.
Corporate venture firms – dedicated followers of fashion?
Eagerly pursuing all the latest fads and trends.
